Click for best price
Lung Cancer Therapeutics Market Size, Share 2023
This report aims to provide a comprehensive presentation of the global market for Lung Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Cancer Therapeutics. This report contains market size and forecasts of Lung Cancer Therapeutics in global, including the following market information:
Global Lung Cancer Therapeutics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Lung Cancer Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Targeted Therapy Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Lung Cancer Therapeutics include AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Roche, Boehringer Ingelheim GmbH, Pfizer, Sanofi S.A., Bristol-Myers Squibb and Novartis, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Lung Cancer Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Lung Cancer Therapeutics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Lung Cancer Therapeutics Market Segment Percentages, by Type, 2022 (%)
Targeted Therapy
Immunotherapy
Chemotherapy
Radiation Therapy
Others
Global Lung Cancer Therapeutics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Lung Cancer Therapeutics Market Segment Percentages, by Application, 2022 (%)
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Global Lung Cancer Therapeutics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Lung Cancer Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Lung Cancer Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Lung Cancer Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Eli Lilly and Company
GlaxoSmithKline
Roche
Boehringer Ingelheim GmbH
Pfizer
Sanofi S.A.
Bristol-Myers Squibb
Novartis
Agennix AG
Outline of Major Chapters:
Chapter 1: Introduces the definition of Lung Cancer Therapeutics, market overview.
Chapter 2: Global Lung Cancer Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Lung Cancer Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Lung Cancer Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Lung Cancer Therapeutics Market, Global Outlook and Forecast 2023-2029 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
60 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Lung Cancer Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Lung Cancer Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Lung Cancer Therapeutics Overall Market Size
2.1 Global Lung Cancer Therapeutics Market Size: 2022 VS 2029
2.2 Global Lung Cancer Therapeutics Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Lung Cancer Therapeutics Players in Global Market
3.2 Top Global Lung Cancer Therapeutics Companies Ranked by Revenue
3.3 Global Lung Cancer Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Lung Cancer Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Lung Cancer Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Lung Cancer Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Lung Cancer Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Lung Cancer Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Lung Cancer Therapeutics Market Size Markets, 2022 & 2029
4.1.2 Targeted Therapy
4.1.3 Immunotherapy
4.1.4 Chemotherapy
4.1.5 Radiation Therapy
4.1.6 Others
4.2 By Type - Global Lung Cancer Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Lung Cancer Therapeutics Revenue, 2018-2023
4.2.2 By Type - Global Lung Cancer Therapeutics Revenue, 2024-2029
4.2.3 By Type - Global Lung Cancer Therapeutics Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Lung Cancer Therapeutics Market Size, 2022 & 2029
5.1.2 Non-Small Cell Lung Cancer (NSCLC)
5.1.3 Small Cell Lung Cancer (SCLC)
5.2 By Application - Global Lung Cancer Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Lung Cancer Therapeutics Revenue, 2018-2023
5.2.2 By Application - Global Lung Cancer Therapeutics Revenue, 2024-2029
5.2.3 By Application - Global Lung Cancer Therapeutics Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Lung Cancer Therapeutics Market Size, 2022 & 2029
6.2 By Region - Global Lung Cancer Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Lung Cancer Therapeutics Revenue, 2018-2023
6.2.2 By Region - Global Lung Cancer Therapeutics Revenue, 2024-2029
6.2.3 By Region - Global Lung Cancer Therapeutics Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Lung Cancer Therapeutics Revenue, 2018-2029
6.3.2 US Lung Cancer Therapeutics Market Size, 2018-2029
6.3.3 Canada Lung Cancer Therapeutics Market Size, 2018-2029
6.3.4 Mexico Lung Cancer Therapeutics Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Lung Cancer Therapeutics Revenue, 2018-2029
6.4.2 Germany Lung Cancer Therapeutics Market Size, 2018-2029
6.4.3 France Lung Cancer Therapeutics Market Size, 2018-2029
6.4.4 U.K. Lung Cancer Therapeutics Market Size, 2018-2029
6.4.5 Italy Lung Cancer Therapeutics Market Size, 2018-2029
6.4.6 Russia Lung Cancer Therapeutics Market Size, 2018-2029
6.4.7 Nordic Countries Lung Cancer Therapeutics Market Size, 2018-2029
6.4.8 Benelux Lung Cancer Therapeutics Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Lung Cancer Therapeutics Revenue, 2018-2029
6.5.2 China Lung Cancer Therapeutics Market Size, 2018-2029
6.5.3 Japan Lung Cancer Therapeutics Market Size, 2018-2029
6.5.4 South Korea Lung Cancer Therapeutics Market Size, 2018-2029
6.5.5 Southeast Asia Lung Cancer Therapeutics Market Size, 2018-2029
6.5.6 India Lung Cancer Therapeutics Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Lung Cancer Therapeutics Revenue, 2018-2029
6.6.2 Brazil Lung Cancer Therapeutics Market Size, 2018-2029
6.6.3 Argentina Lung Cancer Therapeutics Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Lung Cancer Therapeutics Revenue, 2018-2029
6.7.2 Turkey Lung Cancer Therapeutics Market Size, 2018-2029
6.7.3 Israel Lung Cancer Therapeutics Market Size, 2018-2029
6.7.4 Saudi Arabia Lung Cancer Therapeutics Market Size, 2018-2029
6.7.5 UAE Lung Cancer Therapeutics Market Size, 2018-2029
7 Lung Cancer Therapeutics Companies Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Lung Cancer Therapeutics Major Product Offerings
7.1.4 AstraZeneca Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Eli Lilly and Company
7.2.1 Eli Lilly and Company Company Summary
7.2.2 Eli Lilly and Company Business Overview
7.2.3 Eli Lilly and Company Lung Cancer Therapeutics Major Product Offerings
7.2.4 Eli Lilly and Company Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.2.5 Eli Lilly and Company Key News & Latest Developments
7.3 GlaxoSmithKline
7.3.1 GlaxoSmithKline Company Summary
7.3.2 GlaxoSmithKline Business Overview
7.3.3 GlaxoSmithKline Lung Cancer Therapeutics Major Product Offerings
7.3.4 GlaxoSmithKline Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.3.5 GlaxoSmithKline Key News & Latest Developments
7.4 Roche
7.4.1 Roche Company Summary
7.4.2 Roche Business Overview
7.4.3 Roche Lung Cancer Therapeutics Major Product Offerings
7.4.4 Roche Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.4.5 Roche Key News & Latest Developments
7.5 Boehringer Ingelheim GmbH
7.5.1 Boehringer Ingelheim GmbH Company Summary
7.5.2 Boehringer Ingelheim GmbH Business Overview
7.5.3 Boehringer Ingelheim GmbH Lung Cancer Therapeutics Major Product Offerings
7.5.4 Boehringer Ingelheim GmbH Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.5.5 Boehringer Ingelheim GmbH Key News & Latest Developments
7.6 Pfizer
7.6.1 Pfizer Company Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Lung Cancer Therapeutics Major Product Offerings
7.6.4 Pfizer Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.6.5 Pfizer Key News & Latest Developments
7.7 Sanofi S.A.
7.7.1 Sanofi S.A. Company Summary
7.7.2 Sanofi S.A. Business Overview
7.7.3 Sanofi S.A. Lung Cancer Therapeutics Major Product Offerings
7.7.4 Sanofi S.A. Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.7.5 Sanofi S.A. Key News & Latest Developments
7.8 Bristol-Myers Squibb
7.8.1 Bristol-Myers Squibb Company Summary
7.8.2 Bristol-Myers Squibb Business Overview
7.8.3 Bristol-Myers Squibb Lung Cancer Therapeutics Major Product Offerings
7.8.4 Bristol-Myers Squibb Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.8.5 Bristol-Myers Squibb Key News & Latest Developments
7.9 Novartis
7.9.1 Novartis Company Summary
7.9.2 Novartis Business Overview
7.9.3 Novartis Lung Cancer Therapeutics Major Product Offerings
7.9.4 Novartis Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.9.5 Novartis Key News & Latest Developments
7.10 Agennix AG
7.10.1 Agennix AG Company Summary
7.10.2 Agennix AG Business Overview
7.10.3 Agennix AG Lung Cancer Therapeutics Major Product Offerings
7.10.4 Agennix AG Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.10.5 Agennix AG Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Lung Cancer Therapeutics Market Opportunities & Trends in Global Market
Table 2. Lung Cancer Therapeutics Market Drivers in Global Market
Table 3. Lung Cancer Therapeutics Market Restraints in Global Market
Table 4. Key Players of Lung Cancer Therapeutics in Global Market
Table 5. Top Lung Cancer Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Lung Cancer Therapeutics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Lung Cancer Therapeutics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Lung Cancer Therapeutics Product Type
Table 9. List of Global Tier 1 Lung Cancer Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Lung Cancer Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Lung Cancer Therapeutics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Lung Cancer Therapeutics Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2029
Table 30. AstraZeneca Company Summary
Table 31. AstraZeneca Lung Cancer Therapeutics Product Offerings
Table 32. AstraZeneca Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 33. AstraZeneca Key News & Latest Developments
Table 34. Eli Lilly and Company Company Summary
Table 35. Eli Lilly and Company Lung Cancer Therapeutics Product Offerings
Table 36. Eli Lilly and Company Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 37. Eli Lilly and Company Key News & Latest Developments
Table 38. GlaxoSmithKline Company Summary
Table 39. GlaxoSmithKline Lung Cancer Therapeutics Product Offerings
Table 40. GlaxoSmithKline Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 41. GlaxoSmithKline Key News & Latest Developments
Table 42. Roche Company Summary
Table 43. Roche Lung Cancer Therapeutics Product Offerings
Table 44. Roche Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 45. Roche Key News & Latest Developments
Table 46. Boehringer Ingelheim GmbH Company Summary
Table 47. Boehringer Ingelheim GmbH Lung Cancer Therapeutics Product Offerings
Table 48. Boehringer Ingelheim GmbH Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 49. Boehringer Ingelheim GmbH Key News & Latest Developments
Table 50. Pfizer Company Summary
Table 51. Pfizer Lung Cancer Therapeutics Product Offerings
Table 52. Pfizer Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 53. Pfizer Key News & Latest Developments
Table 54. Sanofi S.A. Company Summary
Table 55. Sanofi S.A. Lung Cancer Therapeutics Product Offerings
Table 56. Sanofi S.A. Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 57. Sanofi S.A. Key News & Latest Developments
Table 58. Bristol-Myers Squibb Company Summary
Table 59. Bristol-Myers Squibb Lung Cancer Therapeutics Product Offerings
Table 60. Bristol-Myers Squibb Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 61. Bristol-Myers Squibb Key News & Latest Developments
Table 62. Novartis Company Summary
Table 63. Novartis Lung Cancer Therapeutics Product Offerings
Table 64. Novartis Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 65. Novartis Key News & Latest Developments
Table 66. Agennix AG Company Summary
Table 67. Agennix AG Lung Cancer Therapeutics Product Offerings
Table 68. Agennix AG Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 69. Agennix AG Key News & Latest Developments
List of Figures
Figure 1. Lung Cancer Therapeutics Segment by Type in 2022
Figure 2. Lung Cancer Therapeutics Segment by Application in 2022
Figure 3. Global Lung Cancer Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Lung Cancer Therapeutics Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Lung Cancer Therapeutics Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Lung Cancer Therapeutics Revenue in 2022
Figure 8. By Type - Global Lung Cancer Therapeutics Revenue Market Share, 2018-2029
Figure 9. By Application - Global Lung Cancer Therapeutics Revenue Market Share, 2018-2029
Figure 10. By Type - Global Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Lung Cancer Therapeutics Revenue Market Share, 2018-2029
Figure 12. By Application - Global Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Lung Cancer Therapeutics Revenue Market Share, 2018-2029
Figure 14. By Region - Global Lung Cancer Therapeutics Revenue Market Share, 2018-2029
Figure 15. By Country - North America Lung Cancer Therapeutics Revenue Market Share, 2018-2029
Figure 16. US Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Lung Cancer Therapeutics Revenue Market Share, 2018-2029
Figure 20. Germany Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 21. France Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Lung Cancer Therapeutics Revenue Market Share, 2018-2029
Figure 28. China Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 32. India Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Lung Cancer Therapeutics Revenue Market Share, 2018-2029
Figure 34. Brazil Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Lung Cancer Therapeutics Revenue Market Share, 2018-2029
Figure 37. Turkey Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 41. AstraZeneca Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Eli Lilly and Company Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. GlaxoSmithKline Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Roche Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Boehringer Ingelheim GmbH Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Pfizer Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Sanofi S.A. Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Bristol-Myers Squibb Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Novartis Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Agennix AG Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
